Optimization of a therapeutic electromagnetic field (EMF) to retard breast cancer tumor growth and vascularity by Cameron, Ivan L. et al.
Marshall University
Marshall Digital Scholar
Biochemistry and Microbiology Faculty Research
2014
Optimization of a therapeutic electromagnetic field
(EMF) to retard breast cancer tumor growth and
vascularity
Ivan L. Cameron
Marko S. Markov
W. Elaine Hardman Ph.D.
Marshall University, hardmanw@marshall.edu
Follow this and additional works at: http://mds.marshall.edu/sm_bm
Part of the Medical Sciences Commons
This Article is brought to you for free and open access by the Faculty Research at Marshall Digital Scholar. It has been accepted for inclusion in
Biochemistry and Microbiology by an authorized administrator of Marshall Digital Scholar. For more information, please contact
zhangj@marshall.edu, martj@marshall.edu.
Recommended Citation
Cameron IL, Markov MS, Hardman WE. Optimization of a therapeutic electromagnetic field (EMF) to retard breast cancer tumor
growth and vascularity. Cancer Cell International. 2014;14(1):125.
PRIMARY RESEARCH Open Access
Optimization of a therapeutic electromagnetic
field (EMF) to retard breast cancer tumor growth
and vascularity
Ivan L Cameron1*, Marko S Markov2 and W Elaine Hardman3
Abstract
Background: This study provided additional data on the effects of a therapeutic electromagnetic field (EMF) device
on growth and vascularization of murine 16/C mammary adenocarcinoma cells implanted in C3H/HeJ mice.
Methods: The therapeutic EMF device generated a defined 120 Hz semi sine wave pulse signal of variable intensity.
Murine 16/C mammary adenocarcinoma tumor fragments were implanted subcutaneously between the scapulae of
syngeneic C3H mice. Once the tumor grew to 100 mm3, daily EMF treatments were started by placing the cage of
mice within the EMF field. Treatment ranged from 10 to 20 milli-Tesla (mT) and was given for 3 to 80 minutes either
once or twice a day for 12 days. Tumors were measured and volumes calculated each 3–4 days.
Results: Therapeutic EMF treatment significantly suppressed tumor growth in all 7 EMF treated groups. Exposure to
20mT for 10 minutes twice a day was the most effective tumor growth suppressor. The effect of EMF treatment on
extent of tumor vascularization, necrosis and viable area was determined after euthanasia. The EMF reduced the
vascular (CD31 immunohistochemically positive) volume fraction and increased the necrotic volume of the tumor.
Treatment with 15 mT for 10 min/d gave the maximum anti-angiogenic effect. Lack of a significant correlation
between tumor CD 31 positive area and tumor growth rate indicates a mechanism for suppression of tumor growth
in addition to suppression of tumor vascularization.
Conclusion: It is proposed that EMF therapy aimed at suppression of tumor growth and vascularization may prove
a safe alternative for patients whether they are or are not candidates for conventional cancer therapy.
Keywords: Electromagnetic field (EMF), Breast cancer, Angiogenesis, Immunohistochemical, Endothelial cell marker
(CD31)
Background
A novel electromagnetic field has been reported to safely
reduce growth and vascularization of an implanted breast
cancer in mice [1,2]. The purpose of the present study was
to perform additional animal studies using the “Complex
Magnetic Field Generating Device” (referred to as “mag-
netic device”) on tumor growth in a mouse tumor model.
In this study, the effects of varying treatment doses (mag-
netic field intensities) were evaluated using the murine 16/
C mammary tumor in syngeneic C3H mice.
The magnetic device used was supplied and calibrated
by Bio-Dynamics. This magnetic device generated a rec-
tified semi-sine wave signal of 10 to 20 milli-Tesla (mT)
magnetic field intensity at 120 pulses per second. Dia-
grams of the device and of the waveform are shown in
Figure 1. The cage of tumor-bearing mice was placed on
the shelf inside the coil. Mice were treated with varying
treatment intensities and durations to determine if the
therapeutic EMF caused a significant decrease in the
tumor growth. Table 1 lists the different therapeutic
EMF conditions included in the current report. Data
groups 1, 3, 6, 7 are from [2] and new unpublished data
has been added for groups 2, 4, 5, 8.
Adding the new unpublished experimental data allowed
a more complete analyses of EMF time and field intensity
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needed to best retard tumor growth. The additional new
data also allowed further testing of the hypothesis that the
therapeutic EMF reduces tumor growth rate by reduction
in the extent of tumor vascularization (anti-angiogenesis)
leading to an increase in the extent of tumor necrosis [2].
This report has two separate result sections. The first sec-
tion deals with effects of EMF therapy on tumor growth
and the second section deals with the effects of the EMF
on the vascular, necrotic and viable volume density frac-
tions of the tumors. In brief, the results of this study dem-
onstrate that: 1) tumor growth retardation was related to
increased magnetic field intensity but not to increased time
at a constant intensity and 2) the magnetic field exposure
significantly inhibited tumor vascularization.
Results and discussion
Section 1: Effect of therapeutic electromagnetic field
intensity (the treatment) on growth of subcutaneously
implanted C/16 murine mammary adenocarcinomas
(the tumor) in mice
Therapeutic EMF treatment was for 12 days starting on
day 8 after tumor implantation. By day 8, all tumors had
grown to measurable size (about 5 mm in diameter).
Tumor volume data collection was then initiated. Table 1
shows the treatment conditions of each group. The
treatment groups were subdivided to determine the ef-
fect of: 1) increasing the time of the treatment at a con-
stant intensity (Figure 2) or 2) increasing the intensity of
treatment for a constant time (Figure 3). The data in
Figure 2 and Table 2 indicate that EMF exposure at
10mT intensity did significantly suppress tumor growth
compared to control but that increasing the length of
exposure (from 3 minutes to 10 or 40 minutes per day)
at 10mT intensity did not result in additional suppres-
sion of tumor mass. In fact, there was no difference in
the non-linear regressions (that is, the null hypothesis
that the exponential growth equations were the same
was accepted, analyses by Prism™) of tumor growth at
the three times thus Prism™ provided a single line
(labeled B in Figure 2). The data in Figure 3A shows
increasing intensity of EMF treatment from 10 to 15 to
20 mT did result in dose responsive suppression of
tumor growth compared to control (analyses of the ex-
ponential growth equation resulted in rejecting the null
hypothesis that the lines were the same, Prism™). By day
14, the tumor volume of groups 7 and 8 (the two 20mT
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Figure 1 The complex magnetic field device and illustration of
field generated. A. Drawing illustrating the “Complex Magnetic
Field Device” used in the current study. The ellipsoidal coil with 14”
by 21” diameters targets the EMF exposure area. The magnetic flux
density, as measured within the perforated Plexiglass wall of the
exposure chamber (mouse cage), produces a homogeneous signal
of 10, 15 or 20 mT. The temperature change within the chamber
during mice exposures to therapeutic EMF did not exceed 1˚C.
B. The device generates a pulsating half (semi) sine wave magnetic
field with a frequency of 120 pulses per second, as shown. A small
DC component occurs between two semi-sine waves and a slight
distortion is observed at the front of part of the semi-sine wave.
The type of signal flip-flops the negative part of the sine wave into
a positive thus creating a pulsed semi-sine wave.
Table 1 EMF exposure conditions used in this study
Group number EMF exposure condition
1. Control (0 mT) sham exposure
2. 10 mT 3 minutes per day
3. 10 mT 10 minutes per day
4. 10 mT 40 minutes per day
5. 10 mT 40 minutes twice per day
6. 15 mT 10 minutes per day
7. 20 mT 10 minutes per day
8. 20 mT 10 minutes twice per day
There were 20 mice in group 1, all other groups had 10 mice.
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groups) was significantly less (p = 0.01) and by day 17,
the tumor volume of all groups was significantly less
than of the control group, p = 0.001 (2 way ANOVA,
Prism™). Figure 3B shows that increasing the intensity of
EMF treatment from 10 to 15 to 20 mT at 10 minutes
per treatment did significantly correlate with decreased
tumor volume. This slowing of tumor growth is also sup-
ported by the increase in the calculated tumor doubling
times from 2.12 days (control) to 2.16 days (at 10 mT) to
2.29 days (at 15 mT) to 2.304 days (at 20 mT) (non-linear
analyses of exponential growth curves, Prism™).
Thus, a brief EMF exposure once or twice a day for
nine days resulted in a significant decrease in the mean
tumor size compared to the control group. The specific
claim supported by the analysis of the tumor growth
data is that all treated groups demonstrate slower tumor
growth than in the control (non-EMF treated) group.
Exposure to 10 or 15 or 20mT for 10 minutes per day
caused a dose dependent suppression of the mean tumor
volume to values 25% to 41% of the mean tumor volume
of the control group.
At 20 days after tumor implantation, the non-EMF
treated group of mice had 65% survival. Survival of mice
in the EMF treated groups was dose dependently in-
creased to 93% in the groups that received the 4 highest
EMF dose levels (p = 0.017 for difference from non-EMF
controls by Fishers Exact test, SAS.)
Microscopic pathological findings indicated no evidence
of toxicological or biological abnormalities in any of the
mouse tissues except the spleen. Some of the mice in each
of the eight groups had extramedullary hematopoiesis.
The incidence of extramedullary hematopoiesis in control
mice was 4/10 while the incidence in EMF treated mice
ranged from 3/10 in group 3 to 8/10 in group 8 with no
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Figure 2 Mean tumor volumes of control and treated mice,
constant intensity for increasing time. Mean tumor volume of
control mice (0 EMF, regression line A) or groups of mice exposed to
10mT EMF for increasing time each day starting on day 8 after tumor
cell implantation (regression line B). Statistical analyses (non-linear
analyses of exponential growth curves, Prism™) showed that the mean
tumor volume of all EMF treated groups on day 17 was significantly
smaller than the untreated (sham) control groups. However, there was
not a significant difference between treatment groups.
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Figure 3 Mean tumor volumes of control and treated mice,
increasing intensity for constant time. A. Mean volume (mm3) of
the murine 16/C breast adenocarcinoma tumor in control group and
in the groups of mice exposed to 10, 15 or 20 mT EMF for 10
minutes once a day. Tumors were measured on day 8 just before
the first exposure and again on days 10, 14, 17 and 20. ANOVA
followed by SNK statistical analysis of group data (Table 2) revealed
that by day 17 the tumors in the control group were significantly
larger than the tumors of all treatment groups. B. Linear regression
analyses of tumor volume at 17 days after implantation of mice
receiving either 0, 10 15 or 20 mT EMF for 10 minutes per day
illustrating the significant linear decrease in tumor volume with
increasing EMF intensity.
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apparent relationship to EMF treatment. The increased
extramedullary hematopoiesis was probably due to non-
specific stimulation of the immune system by the presence
of the tumor. The implanted tumors all showed pathology
typical of mammary gland neoplasms.
Section 2: Effect of an electromagnetic field
(the treatment) on vascular area and viable and necrotic
tumor volume of subcutaneously implanted C/16 murine
mammary adenocarcinomas (the tumor) in mice
Tissue cells receive oxygen and nutrients by diffusion
from blood vessels. However, cells must be located
within about 150 μm of a blood vessel for diffusion to
adequately meet the oxygen and nutrient requirements for
cell viability. Thus, growth and viability of the tumor is
dependent on vascularization of the tumor by angiogen-
esis (the formation of new blood vessels). If the production
of tumor cells is faster than vascularization of the new
tumor tissue, then those cells further than 75 to 150 μm
from a blood vessel will die. Any intervention that inter-
feres with tumor angiogenesis can limit the growth of a
tumor. This second section of the report deals with the ef-
fects of the various EMF treatment protocols on the ex-
tent of tumor vascularization and on the extent of viable
and necrotic tumor volume fraction in tumors excised
from mice at the termination of the experiment, 20 days
after tumor transplantation and following 12 days of treat-
ment. Data on tumors from mice that died prior to the
termination of the experiment, at 20 days, were not in-
cluded in this section of the report.
Immunohistochemistry and morphometric analysis of
cryosections
The results for the CD 31 positive area expressed as the
percent of area of the total tumor area, are summarized in
Table 3 and Figure 4. Figure 4A illustrates that the percent
of CD 31 positive area was decreased by EMF treatment.
Figure 4B shows the significant negative relationship be-
tween the necrotic fraction and the percent of CD 31 area.
The EMF treatment at 15 mT per day gave the largest ex-
tent of necrotic tumor volume (least fraction of % area
positive for CD 31) and approached the plateau of max-
imum therapeutic effectiveness in this study.
The results illustrated in Figure 5A show that the % of
CD 31 positive area was significantly related to the vi-
able tumor fraction. However, Figure 5B illustrates that
the CD 31 positive area is not significantly related to
tumor growth. This could be interrupted to mean that
blood supply is critical to tumor survival however ad-
equate blood supply does not guarantee tumor growth.
Cells may be dying or cell cycle may be arrested, thus
growth will be slowed, even in the presence of adequate
blood supply.
Review of EMF treatment conditions used to retard tumor
growth
The EMF exposure conditions used in the present and
past literature reports are summarized in Table 4. The
data in Table 4 indicates significant reduction of tumor
growth in the different cancer tissue cell types studied.
The effective pulse frequencies used range from 0.16 to
480 Hz and from 0.6 mT to 250 mT. All treatments
were given either once or twice a day. Both sine wave
and semi sine wave frequency signals significantly re-
tarded tumor growth. No known comparative study has
been reported to determine the wave form that best re-
tards tumor growth [3].
The current study found that lengthening the duration
of exposure to a 10 mT, 120 Hz semi sine wave EMF sig-
nal from between 3 to 40 minutes once a day did not
significantly increase retardation of tumor growth. How-
ever, increasing the intensity of exposure from 10 to 15
to 20 mT for 10 minutes did dose responsively increase
the tumor doubling time. Exposure to 20 mT for 10 mi-
nutes twice a day gave the longest lengthening of tumor
growth doubling time. In another study Tatatova et al.
[10] reported that increasing daily exposure to 1 Hz at
100 mT for 60 or 180 min did not cause significant re-
tardation of tumor growth but exposure for 360 minutes
twice a day did cause a significant reduction.
None of the EMF conditions reviewed resulted in
tumor regression. Thus more research is still needed on
the optimization of EMF exposure condition for cancer
therapy however slowed tumor growth without adverse
side effects could still provide clinical benefit for patients
Table 2 Tumor volumes for each group, as defined in
Table 1 at 8, 10, 14 and 17 days after implantation of
tumors
Group Day 8 Day 10 Day 14 Day 17
1 138.5 ± 37.2 370.3 ± 184.0 1602.0 ± 845.2 4089.1 ± 1341.6a
2 130.9 ± 39.2 282.3 ± 140.9 1320.8 ± 529.0 3149.8 ± 727.0
3 137.1 ± 37.0 308.0 ± 125.8 1207.2 ± 445.5 3081.9 ± 553.0
4 111.2 ± 36.6 294.9 ± 132.2 1095.2 ± 382.6 2901.9 ± 696.2
5 129.8 ± 39.2 275.4 ± 114.1 1306.7 ± 440.3 3194.5 ± 524.5
6 132.6 ± 43.3 264.9 ± 96.2 1181.5 ± 630.9 2742.2 ± 784.6
7 123.4 ± 44.0 261.1 ± 166.3 1057.5 ± 528.6 2473.0 ± 756.5
8 142.2 ± 44.3 225.9 ± 81.8 922.0 ± 303.7 2402.8 ± 562.6
P valueb 0.71 0.24 0.05 0.0001
aMeans of the tumor volume for each group were not significantly different
until day 14. ANOVA followed by SNK showed that on Day 14 the tumor
volume of group 1 was significantly greater than that of groups 7 and 8 and
that on Day 17, the tumor volume of Group 1 was significantly greater than
that of all other groups. Group 1 had 20 mice, all other groups had 10 mice.
bP value from the ANOVA. The decreasing p value with time indicates that the
differences between groups were increasing with time.
Tumor volume (mm3, mean ± SD).
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in combination or independent from conventional can-
cer chemo- or irradiation therapies.
Mechanism of action of EMF on retardation of tumor
growth
Data in the current and past reports [1,2] suggests that a
therapeutic EMF semi-sine wave at 120 Hz at 10 to 20 mT
for 10 minutes a day caused a significant retardation of
tumor growth accompanied by a decrease in tumor
vascularization and an increase in tumor necrotic volume
fraction. Figure 5 reveals the vascular volume fraction (CD
31 positive) of the tumor to be an excellent predictor of
the necrotic tumor volume fraction and Figure 4 shows
that an EMF intensity of 15 mT for 10 minutes a day was
an optimal exposure, in this study, to decrease tumor vas-
cular area and to increase the resulting tumor cell necrosis.
Figures 6, A,B and 7 (from Cameron et al. [14]) illus-
trate that tumor cancer cells do not survive at distances
of greater than 100–150 μm from a blood vessel. Tumor
cancer cells that lack adequate oxygen become hypoxic
and begin to produce hypoxia inducing factor (HIF- α).
Vascular endothelial cells respond by sprouting endothe-
lial cell pseudopods to project into the hypoxic regions
of tumor cells and then form a vacuole/lumen that al-
lows entrance of blood element, nutrients and oxygen
into the hypoxic cell area [14]. The surviving tumor cells
can then continue cell growth and proliferation. This
vascularization process is termed tumor angiogenesis
and any condition that interferes with this process is said
to be anti-angiogenic. The current report and a prior re-
port [14] demonstrate that an EMF treatment of 15 mT
for 10 minutes a day is a safe and effective therapy for
retardation of tumor vascularization, tumor growth and
metastasis.
Therapeutic EMF treatment options
Neither the current study nor any of the past studies on
use of EMF on tumor growth (Table 4) give evidence
that EMF treatment resulted in tumor regression to
smaller size. From this observation one can conclude
that use of therapeutic EMF does not appear to provide
a possible sole (stand-alone) cure for tumor cancer pa-
tients. However, therapeutic EMF has proved a safe and
effective adjuvant therapy when used in conjunction
with gamma irradiation treatment [1]. The proposed rea-
son for combining both therapeutic EMF and irradiation
therapies was that each treatment focused on a different
target. Irradiation and most cancer chemotherapy drugs
focus on direct killing of rapidly proliferating cells while
EMF appears to focus on retarding of cancerous tumor
angiogenesis. The only other place in the unwounded adult
human body that might require significant angiogenesis is
during regrowth of uterine mucosal vascularization follow-
ing menstruation in women. Thus harmful side effects of
therapeutic EMF on angiogenesis in the normal adult un-
wounded body are very limited. The anti-angiogenesis
action of therapeutic EMF appears to deprive the cancer
cells of needed nutrients and oxygen and they die. Anti-
angiogenesis agents can also interfere with tumor vascular
metastasis [1].
Thus one can reasonably expect an additive or perhaps a
synergistic effect of combining two different targets (anti-
angiogenesis and anti-rapidly dividing cells) for treatment
of cancer. Given that rapidly dividing cell populations are
Table 3 Effect of the EMF treatments on the extent of vascular (CD31 positive) necrotic and viable tissue in tumors
taken from mice sacrificed 20 days after tumor implantation
Group N Total tumor volume (mm3) Viable tumor volume (mm3) Necrotic tumor volume (mm3) Necrotic fraction % CD 31 positive
1 11 5084.7 ± 1257 3776.0 ± 884.4 1308.7 ± 425.9 0.25 ± 0.03 7.50 ± 2.4
2 8 4442.3 ± 884.6 3282.2 ± 691.1 1160.1 ± 268.6 0.26 ± 0.04 6.90 ± 2.0
3 6 4077.5 ± 579.8 2796.4 ± 392.1 1281.1 ± 225.0 0.31 ± 0.03 4.46 ± 1.1
4 9 3598.9 ± 964.2 2475.0 ± 691.7 1123.9 ± 278.3 0.31 ± 0.02 4.37 ± 0.7
5 9 4330.8 ± 295.4 2818.1 ± 614.4 1512.7 ± 304.6 0.35 ± 0.03 3.27 ± 0.8
6 7 3799.0 ± 480.4 2221.8 ± 753.9 1577.2 ± 663.2 0.41 ± 0.07 2.24 ± 1.1
7 8 3958.8 ± 244.6 2534.7 ± 497.8 1424.1 ± 255.7 0.36 ± 0.02 2.99 ± 0.6
8 9 3678.1 ± 599.3 2450.8 ± 397.6 1227.3 ± 290.9 0.33 ± 0.05 3.96 ± 1.5
Analysis of variance followed by a Student-Newman-Keuls multiple range test showed the following significant difference (p < 0.05) between the group means:
Volume of viable tumor – the viable tumor volume of group 1 was significantly greater than the viable tumor volume of groups 3 to 8; the viable tumor volume
of group 2 was significantly greater than the viable tumor volume of group 6.
Necrotic fraction – the necrotic fractions of groups 1 and 2 were significantly less than the necrotic fractions of groups 3 and 8; the necrotic fraction of group 6
was significantly greater than the necrotic fraction of all other groups.
% CD 31 positive – the CD 31 positive areas (volume fraction) of groups 1 and 2 were significantly greater than the CD 31 positive area of groups 3 to 8; the CD
31 positive areas of groups 3 and 4 were significantly greater than the CD 31 positive area of group 6.
Total tumor volume – the total tumor volume of group 1 was significantly greater than the total tumor mass of all other groups.
All values are mean ± SD.
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normally present throughout the body it follows that vas-
cular delivery of cancer chemotherapeutic drugs that target
dividing cells can also cause a number of harmful side
effects in rapidly dividing normal tissues. However, ir-
radiation therapy can be targeted to cancerous areas to
help minimize this harmful side effect. In one study the
combination of gamma irradiation and therapeutic EMF
did have a significant additive inhibitory effect on tumor-
ous breast cancer growth and metastasis [1].
Conclusions
It is concluded that an appropriate therapeutic EMF as
summarized in this report can safely reduce tumor
growth and vascularization and can be a useful adjuvant
for increasing the efficacy of conventional cancer therap-
ies [1,8,12,15,16].
Materials and methods
The C3H/HeJ mice used were obtained from the Frederick
Cancer Research and Development Center of the National
Cancer Institute (Frederick, MD). The C3H mice were ap-
proximately 7 weeks of age at the initiation of the study.
Mice were housed in plastic micro-isolator cages with
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Figure 4 Vascular and necrotic tumor fractions after EMF
treatment. A. Therapeutic EMF on the percent of tumor area
immunohistochemically positive for CD 31 (a measure of tumor
vascular volume fraction). The mean CD 31- positive area of each
tumor treatment group is shown in the scattergram. Statistical
analysis (ANOVA followed by SNK post-hoc test) revealed the mean
of CD 31 positive area of control group # 1 to be significantly
greater than of treatment groups 3 to 8 and groups 3 and 4 to be
significantly greater than group 6. B. Significant, one phase decay
relationship between CD 31positive area and the necrotic fraction
of tumors after EMF treatment.
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Figure 5 Relationships between CD32 positive fraction, viable
tumor volume and growth rates of EMF treated tumors. A. The
significant, linear relationship between the CD 31 positive fraction and
the viable tumor volume of tumors. B. The non-significant relationship
between the CD 31 positive fraction and the growth rate of the
tumors. Taken together, these data illustrate that blood supply (CD 31
positive fraction) is critical for tumor viability but is not related to
tumor growth.
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sterile hardwood bedding. They received standard labora-
tory diet and filtered tap water ad libitum. Air temperature
and relative humidity in the animal rooms were controlled
at 74 ± 2 F and approximately 50 ± 10%, respectively. Lights
in the animal rooms were operated automatically on 12-
hour light/dark cycles. The murine 16/C mammary adeno-
carcinoma tumor was used. Tumors were maintained in
routine subcutaneous (s.c.) passage in vivo in C3H mice
prior to implantation of tumor fragments.
Tumor implantation: Equal sized fragments of a C/16
murine mammary adenocarcinoma were implanted sub-
cutaneously between the scapulae of C3H mice. EMF
treatment was started on day 8 after tumor implantation
and continued for 12 days. By day 8, all tumors had
grown to measurable size (about 5 mm) and tumor vol-
ume measures began. The mice were placed within the
magnetic device once or twice a day.
At termination of the study, the primary tumors were
dissected from the backs of the mice, weighed, bisected
on a plane perpendicular to the backs of the mice and
frozen in O.C.T. Compound (Tissue-Tek, Elkhardt, IN).
Cryosections, cut approximately 12–15 μM thick, were
placed on negatively charged 100 μM gap ChemMate
slides (Ventana, Tucson, AZ) air dried for at least
24 hours and fixed in acetone. Immunohistochemical
staining was performed on a TechMate Automated
Staining System (Ventana) with the ChemMate buffer
solutions kit (Ventana). Sections from each tumor were
stained with either monoclonal rat anti-mouse CD-31
(PharMingen, San Diego, CA) or a rat IgG2a isotype
control (Pharmingen, San Diego, CA to demonstrate
specificity) followed by biotinylated rabbit anti-rat
immunoglobulin (Dako, Carpinteria, CA). Binding was
demonstrated with streptavidin-horseradish peroxidase
(Vector Laboratories, Burlingame, CA) and diaminobenzi-
dine (Vector). Slides were dehydrated, coverslipped with
Permount (Fisher, Atlanta, GA), and analyzed. CD31 is a
130 kDa integral membrane protein that mediates cell-to-
cell adhesion and is expressed on the surface of endothelial
cells. The positive staining was identified and quantified
using phase contract microscopy and grid intercept point
counting.
Morphometric analyses for the percent of necrotic tissue,
viable fraction and CD 31 positive was performed on a
subset of 51 tumors randomly sampled from each treat-
ment group. Tumor sections stained for CD 31 but lacking
a counterstain were studied using phase contrast micros-
copy. This optical technique allowed differentiation of nec-
rotic, viable and CD 31 stained regions of each tumor.
Grid intercept point counting was used to estimate the
fraction of an area covered by specific structures. To per-
form intercept point counting, an ocular grid is placed in
the microscope eyepiece to superimpose a grid image over
the microscope field. The number of intercepts overlying
each structure, divided by the total number of intercepts
on the grid estimated the fraction of the area covered by
the structure.
Histopathological evaluation of brain, small intestine,
kidney, heart, liver and spleen was performed on 5 μM
thick sections of formalin fixed, paraffin embedded tissue
Table 4 A sample of literature reports on effects of electromagnetic field types on growth of cancerous tumors in
animal hostsa
Type of tumor Frequency Hz
and (pps)
Intensity Tesla Exposure min (m), (hr),
or sec/day (d)
Significant growth
retardation
yes or no
References
Melanoma 25 2-5 mT 3 hr/d Yes Hu et al. 2010 [4]
Hepatoma 100 0.7 mT 1 hr 3x/d Yes Wen et al. 2011 [5]
Colon 50 2.5 & 5.5 mT 70 m/d Yes Tofani et al. 2002 [6]
Mammary 12 & 460 9 mT 10 m on alternate days Yes Bellossi & Desplasi 1991 [7]
MX-1 50 15-20 mT 3 hr/d Yes Berg et al. 2010 [8]
Carcinogen induced 0.8 100 mT 8 hr/d Yes Seze et al. 2000 [9]
Mammary 120b 10-20 mT 10 m/d Yes Williams 2001 [2]
Mammary 120b 10 & 20 mT 3 to 80 m/d Yes Cameron et al. this report
Mammary 120b 15 mT 10 m/d Yes Cameron et al. 2005 [1]
Mammary 1 100 mT 60 to 180 m/d No Tataova et al. 2011 [10]
1 360 m/d Yes
Sarcoma 0.16 – 1.3 0.6 – 2.0 T 15 m/d Yes Zhang et al. 2002 [11]
Melanoma 50 5.5 mT 70 m/d Yes Tofani et al. 2003 [12]
Sarcoma 50 250 mT 80 sec/d Yes Yamaguch et al. 2006 [13]
aThis sample is not comprehensive but is judged to be a reasonably representative.
bA semi sine wave was used in these studies, other studies used a sine wave signal.
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that were stained with hematoxylin and eosin. Samples
were from all mice in the study groups.
Statistical analyses: All data on each tumor were entered
into an Excel spreadsheet. Excel was used to generate all
calculated variables. SAS or Prism™ software (Prism 5™,
Graphpad Software, San Diego, CA) were used to deter-
mine means and standard deviations and for analysis of
variance (ANOVA) followed by Student-Newman-Keuls
or Bonferroni post-hoc tests. Parametric types of analyses
can be performed if: 1) the distribution of the data is not
significantly different from a normal distribution, 2) the
variances of the groups are not significantly different and
3) the treatment groups are independent. Data were found
to fit the requirements for parametric analyses.
Tumor volume at each time point, by each treatment
was analyzed by 2-way ANOVA followed by a Bonferroni
post-hoc test using Prism™.
Prism™ was used to generate all graphs and for ana-
lyses of the graphical data. Non-linear regression analysis
using an exponential growth fit was used for the growth
curves then statistical differences between the curves
were calculated using an F-test. The general exponential
growth curve is: Y = Y0*exp(k*X) where k is the rate
constant (reciprocal of the X axis time units) and X is
the time. The doubling time is an estimate of the time
for tumor size to double is computed as the ln(2)/K.
A one phase decay model best fit the CD 31 necrotic
fraction data. The general formula for this model is: Y =
*
*
*
*
*
A
B
Figure 6 Photomicrographs of CD31 immunostained tumor. A. 100X original magnification. B. 250X original magnification. The photomicrographs
are of 12 to 15 μm thick sections of a C/16 murine mammary adenocarcinoma after immunohistochemistry to detect the presence of CD 31 antigen, a
marker for blood vessels. Blood vessels (arrowheads) are visualized by the presence of the dark stain for CD 31. Areas of viable tissue are seen adjacent to
the blood vessels. Necrotic areas (*) are located further from the blood vessels and contain condensed nuclei and cell fragments. Notice the regular
spacing of necrotic and viable areas.
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(Y0 - Plateau)*exp(−K*X) + Plateau. Where ‘plateau’ is
the point at which the curve levels (i.e. more CD 31
positive did not further decrease the necrotic fraction,
0.03 for this equation) and k is the rate constant (0.12
for this equation/% of CD 31 positive). This makes sense
because the necrosis is related to the square of the dis-
tance from a blood vessel, if blood vessels are few, the
amount of necrosis will be high.
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